Jeffrey Schlom Selected Research

Radiotherapy

1/2021	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
1/2018	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
1/2018	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).
9/2013	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
11/2011	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
8/2010	A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
8/2008	Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
9/2007	Synergistic antitumor activity of immune strategies combined with radiation.
1/2007	Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
5/2006	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Schlom Research Topics

Disease

212	Neoplasms (Cancer) 03/2024 - 01/2002
50	Carcinoma (Carcinomatosis) 01/2023 - 09/2002
45	Prostatic Neoplasms (Prostate Cancer) 05/2023 - 01/2002
26	Vaccinia 05/2023 - 01/2002
20	Neoplasm Metastasis (Metastasis) 10/2023 - 06/2003
19	Fowlpox 05/2023 - 10/2002
10	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2010
8	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 09/2002
8	Chordoma 01/2021 - 03/2015
7	Infections 01/2021 - 07/2004
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 01/2013
6	Necrosis 08/2023 - 04/2014
6	Adenocarcinoma 10/2015 - 01/2002
5	Disease Progression 05/2023 - 02/2006
5	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 09/2002
5	Human Influenza (Influenza) 01/2021 - 09/2007
5	Urinary Bladder Neoplasms (Bladder Cancer) 11/2019 - 08/2009
4	Triple Negative Breast Neoplasms 05/2024 - 01/2021
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2002
4	Lung Neoplasms (Lung Cancer) 01/2020 - 06/2008
4	Communicable Diseases (Infectious Diseases) 05/2016 - 01/2008
4	Ovarian Neoplasms (Ovarian Cancer) 11/2011 - 09/2002
3	Injection Site Reaction 01/2023 - 03/2014
3	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 10/2015
3	Squamous Cell Carcinoma of Head and Neck 01/2022 - 03/2006
3	COVID-19 01/2021 - 10/2020
3	Mesothelioma 11/2016 - 09/2005
3	Hematologic Neoplasms (Hematological Malignancy) 02/2014 - 08/2008
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2010 - 11/2005

Drug/Important Bio-Agent (IBA)

122	VaccinesIBA 10/2023 - 01/2002
60	AntigensIBA 11/2023 - 01/2002
32	Cancer VaccinesIBA 01/2023 - 09/2002
27	Carcinoembryonic AntigenIBA 09/2017 - 01/2002
25	Proteins (Proteins, Gene)FDA Link 03/2024 - 03/2004
22	Monoclonal AntibodiesIBA 01/2023 - 05/2002
20	Prostate-Specific Antigen (Semenogelase)IBA 05/2023 - 01/2002
20	avelumabIBA 01/2023 - 10/2015
19	Brachyury protein (Brachyury)IBA 01/2021 - 04/2007
18	Interleukin-12 (IL 12)IBA 08/2023 - 08/2009
18	Immunoglobulin G (IgG)IBA 01/2023 - 04/2002
17	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2016
17	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2002
16	PROSTVACIBA 05/2023 - 02/2011
15	Peptides (Polypeptides)IBA 01/2021 - 01/2002
14	CytokinesIBA 12/2023 - 12/2007
14	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2007
13	Interleukin-15 (Interleukin 15)IBA 12/2023 - 03/2007
13	EpitopesIBA 01/2017 - 01/2002
12	LigandsIBA 03/2024 - 10/2012
11	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 09/2017 - 10/2002
10	Docetaxel (Taxotere)FDA Link 08/2023 - 02/2006
9	AutoantigensIBA 11/2017 - 01/2002
8	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 10/2007
8	B7-H1 AntigenIBA 01/2022 - 01/2018
8	CD58 Antigens (LFA-3)IBA 09/2017 - 10/2002
7	ALT-803IBA 03/2023 - 09/2017
7	AntibodiesIBA 01/2021 - 04/2006
7	B7 AntigensIBA 08/2019 - 10/2002
6	AndrogensIBA 01/2021 - 10/2002
6	Granzymes (Granzyme)IBA 01/2020 - 08/2007
5	NivolumabIBA 05/2024 - 01/2023
5	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2017
5	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2018
5	entinostat (MS 275)IBA 01/2022 - 01/2018
5	PerforinIBA 01/2017 - 09/2002
5	Interleukin-2 (IL2)IBA 12/2016 - 05/2003
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2016 - 05/2003
5	HLA-A2 Antigen (HLA A2 Antigen)IBA 12/2014 - 03/2004
4	Histones (Histone)IBA 01/2023 - 01/2019
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 11/2009
4	Tamoxifen FDA LinkGeneric 01/2021 - 10/2013
4	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
4	Glycoproteins (Glycoprotein)IBA 01/2017 - 09/2002
4	Messenger RNA (mRNA)IBA 05/2014 - 01/2002
4	IpilimumabIBA 04/2014 - 02/2007
4	Hormones (Hormone)IBA 07/2008 - 08/2005
3	Capecitabine (Xeloda)FDA Link 05/2024 - 12/2023
3	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2024 - 04/2018
3	ChemokinesIBA 10/2023 - 09/2005
3	InterferonsIBA 10/2023 - 11/2016
3	sipuleucel-T (APC8015)FDA Link 01/2023 - 07/2012
3	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 09/2002
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 02/2021 - 03/2010
3	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 01/2021 - 08/2019
3	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2021 - 01/2020
3	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2017
3	Cetuximab (Erbitux)FDA Link 01/2020 - 12/2016
3	Therapeutic UsesIBA 11/2019 - 03/2005
3	InterleukinsIBA 04/2018 - 03/2007
3	Radioisotopes (Radionuclides)IBA 01/2016 - 04/2002
3	Synthetic Vaccines (Recombinant Vaccines)IBA 10/2013 - 12/2007
3	CD40 Ligand (CD40L)IBA 10/2012 - 07/2004
3	ChitosanIBA 09/2010 - 03/2007
3	lymphotactinIBA 08/2007 - 11/2003

Therapy/Procedure

95	Therapeutics 03/2024 - 01/2002
71	Immunotherapy 03/2024 - 01/2002
20	Drug Therapy (Chemotherapy) 03/2024 - 09/2002
16	Castration 01/2023 - 07/2008
11	Radiotherapy 01/2021 - 05/2005
4	Radioimmunotherapy 04/2006 - 04/2002